Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data
BioSpace
The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.
Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico
BioSpace
After divorcing Denali Therapeutics earlier this month, Takeda is now splitting up with Veritas In Silico, pulling back from a partnership that advanced novel small-molecule drugs targeting mRNA.
Parkinson’s charity partners Biognosys on biomarker project
Pharmaphorum
A new R D project will try to develop assays for LRRK2, a biomarker linked to Parkinson’s that has emerged as a major drug target in the disease.
Daiichi exits OTC, with $1.55bn unit sale to Suntory
Pharmaphorum
Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.
BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut
BioSpace
Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data expected later this year.
Whitepaper: CDMOs at a Crossroads
BioSpace
In this whitepaper, BioSpace reviews the major trends impacting the CDMO sector and the evolving relationship between sponsors and providers.
Scientists issue call to arms over antifungal resistance
Pharmaphorum
Infectious disease experts from around the world are calling for concerted action to combat a “silent surge” in resistance to antifungal drugs.
Amazon launches AI drug discovery platform
Pharmaceutical Technology
Amazon has already collaborated with Memorial Sloan Kettering Cancer Center with its AI drug discovery software.
J&J leans on Tremfya, cancer drugs to overcome Stelara losses
BioPharma Dive
A growing multiple myeloma franchise helped the pharmaceutical giant top Wall Street s expectations and surpass $15 billion in first-quarter drug sales.
With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026
BioSpace
With robust sales performance from oncology darling Darzalex and immunology superstar Tremfya, Johnson & Johnson is “off to a fast start in 2026,” CEO Joaquin Duato told investors on Tuesday.
Lilly boosts ADC portfolio with CrossBridge Bio deal
BioPharma Dive
Worth up to $300 million, the buyout is Lilly s latest of an ADC maker and adds technology for making dual-payload therapies.
Lilly investing billions to prepare for overseas oral GLP-1 launches
BioSpace
With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity dr
FDA renews criticism of trial sponsors over transparency
Pharmaphorum
The FDA has launched a drive to get clinical trial sponsors to disclose the results of studies – even if they are negative.
Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update
Drug Channels
It’s time for Drug Channels Institute’s (DCI) annual update of vertical integration among insurers, PBMs, specialty pharmacies, and healthcare services within U.S.
Novo Nordisk partners OpenAI on R&D “transformation”
Pharmaphorum
Seeking an R D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.
Travere Therapeutics gains FDA approval for sparsentan in FSGS
Pharmaceutical Business Review
The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition.
Travere Therapeutics gains FDA approval for sparsentan in FSGS
Pharmaceutical Technology
Travere Therapeutics has received FDA approval for Filspari to reduce proteinuria in patients aged eight years and over with FSGS without nephrotic syndrome.
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority
Pharmaceutical Business Review
The treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy.